Pino-Barrio, Maria José
Giménez, Yari
Villanueva, Mariela
Hildenbeutel, Marcus
Sánchez-Dominguez, Rebeca
Rodríguez-Perales, Sandra
Pujol, Roser
Surrallés, Jordi
Río, Paula
Cathomen, Toni http://orcid.org/0000-0002-7757-4630
Mussolino, Claudio
Bueren, Juan Antonio
Navarro, Susana
Article History
Received: 30 May 2019
Accepted: 28 February 2020
First Online: 24 April 2020
Competing interests
: The Division of Hematopoietic Innovative Therapies receives funding from Rocket Pharma. J.A. Bueren is a consultant for Rocket Pharmaceuticals. The rest of the authors declare no competing financial interests.